Brigatinib/Brigatinib belongs to the first generation of targeted therapy drugs

Brigatinib (Brigatinib) is a second-generation ALK-targeted therapy drug. It is mainly used to treat non-small cell lung cancer (NSCLC) with positive ALK (anaplastic lymphoma kinase) gene rearrangement. As a second-generation ALK inhibitor, brigatinib was originally designed to solve the problem of disease progression after resistance to previous-generation ALK inhibitors (such as crizotinib). It has stronger selectivity and targeting activity and can inhibit multiple ALK mutation subtypes, including the common G1202R resistance mutation. This type of mutation is one of the main reasons for the failure of first-generation ALK inhibitors such as crizotinib.

The clinical application of brigatinib was first approved by the FDAfor patients with ALK-positive metastatic non-small cell lung cancer who have progressed on crizotinib treatment. Subsequently, due to its advantages in progression-free survival (PFS) and central nervous system (CNS) metastasis control, it was further approved as a first-line treatment for ALK-positive NSCLC. In a pivotal clinical trial called ALTA-1L, brigatinib was compared head-to-head with crizotinib, and the results showed that it had significant advantages in extending disease control time and reducing the risk of brain metastases, especially for patients with brain metastases at the time of initial diagnosis.

In addition to its potent inhibition ofALK mutations, brigatinib also has a certain degree of ROS1 inhibition, which lays the foundation for its future potential in ROS1 fusion lung cancer. In general, brigatinib, as the second generation ALK-TKI, can not only effectively overcome the resistance of the previous generation of drugs, but also play a good role in the lesions of the central nervous system. It is a key link in the treatment path for patients with ALK-positive lung cancer. Its broad-spectrum and high-efficiency molecular properties mark another important progress in precision medicine in the field of lung cancer treatment.

Reference materials:https://www.alunbrig.com/